Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 174
- Registration Number
- NCT04884035
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺Local Institution - 501, Adelaide, South Australia, Australia
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2022-09-16
- Target Recruit Count
- 78
- Registration Number
- NCT04835870
- Locations
- 🇨🇳
The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 899
- Registration Number
- NCT04824092
- Locations
- 🇨🇳
Morphsys Research Site, Taoyuan, Taiwan
🇬🇧MorphoSys Research Site, Wolverhampton, United Kingdom
🇷🇺Morphosys research site, UFA, Russian Federation
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Conditions
- Angioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaFollicular T-Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypePeripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 170
- Registration Number
- NCT04803201
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Memorial Hospital East, Shiloh, Illinois, United States
🇺🇸University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT04796012
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Myeloid LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT04752163
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 25
- Registration Number
- NCT04747912
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT04668365
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04660799
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun City, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳Fujian Provincial Cancer Hospital, Fuzhou City, China
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2022-11-01
- Target Recruit Count
- 300
- Registration Number
- NCT04638790
- Locations
- 🇮🇳
Tata Memorial Hospital, Mumbai, OPD-81 Main building, Dr. E Borges Road, Parel 400012, India
🇷🇺The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.